Oxagen
A biopharmaceutical company developing small molecule drugs addressing asthma, and chronic allergic and inflammatory conditions.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
$26.7m | Series C | ||
| Total Funding | 000k | ||
| GBP | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 113 % | 40 % | (80 %) | (74 %) | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (6775 %) | (825 %) | (494 %) | (1333 %) | (100 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (6519 %) | (757 %) | (436 %) | (1039 %) | (40 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Oxagen Limited is a privately held biopharmaceutical company focused on developing innovative treatments for respiratory and allergic conditions. The company has licensed rights to an experimental medicine called OC000459, a once-daily oral CRTH2 antagonist. This drug has shown promising results in treating eosinophilic asthma and allergic rhinoconjunctivitis, conditions characterized by inflammation and allergic reactions. Oxagen operates in the biopharmaceutical market, targeting healthcare providers and patients in need of advanced therapeutic options. The company generates revenue through licensing agreements and partnerships with other biotech firms, such as Atopix Therapeutics Limited and Eleventa LLC. These collaborations allow Oxagen to expand its market reach and leverage additional expertise in drug development.
Keywords: biopharmaceutical, CRTH2 antagonist, eosinophilic asthma, allergic rhinoconjunctivitis, OC000459, respiratory conditions, allergic conditions, licensing agreements, drug development, healthcare providers.